Argent Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Argent Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-88,000	Closed	-$1.46M	–	224
2016 Q1	$1.46M	Buy	+88,000	New	+$1.54M	0.07%	112
2014 Q3	–	Sell	-151,100	Closed	-$2.39M	–	167
2014 Q2	$2.39M	Buy	+151,100	New	+$2.16M	0.13%	97

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Argent Capital Management's HZNP Position: Q2 2016 in Review

Argent Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2016, closing a stake of 88,000 shares — an estimated $1.46M sold.

Argent Capital Management first reported a position in HZNP in Q2 2014 and held it in 2 quarters. The position peaked at $2.39M in Q2 2014. 198 funds tracked by Wall St. Rank hold HZNP as of Q2 2016.

Argent Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2016 after selling out during the quarter.
Argent Capital Management sold 88,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2016, an estimated $1.46M.
Argent Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 2 quarters.
Argent Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.39M in Q2 2014.
198 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2016.

Based on Argent Capital Management's 13F filing for Q2 2016, filed 8 Aug 2016.